2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. FABP

FABP

Fatty acid-binding protein

FABP

Related Products

PDF 0.13 MB

Fatty acid-binding proteins (FABPs) are members of the intracellular lipid-binding protein (iLBP) family and are involved in reversibly binding intracellular hydrophobic ligands and trafficking them throughout cellular compartments, including the peroxisomes, mitochondria, endoplasmic reticulum and nucleus. FABPs have broad specificity, including the ability to bind long-chain (C16-C20) fatty acids, eicosanoids, bile salts and peroxisome proliferators. FABPs demonstrate strong evolutionary conservation and are present in a spectrum of species including Drosophila melanogaster, Caenorhabditis elegans, mouse and human.

FABPs are widely expressed throughout the body and play an integral role in a multitude of physiological processes such as lipid metabolism, inflammation and neuronal signaling. FABPs of the mammalian central and peripheral nervous systems have been shown to facilitate the intracellular transport of NAEs, particularly the endocannabinoid arachidonoyl ethanolamide (anandamide, AEA), as well as catabolism by the endoplasmic reticulum-localized enzyme fatty acid amide hydrolase (FAAH).

Most mammals produce 12 distinct subtypes of FABPs, although humans produce up to 10. These include liver-(L-FABP, FABP1), intestine-(I-FABP, FABP2), heart-(H-FABP, FABP3), adipocyte-(A-FABP, FABP4), epidermal-(E-FABP, FABP5), ileal-(Il-FABP, FABP6), brain-(B-FABP, FABP7), myelin-(M-FABP, FABP8), testis-(T-FABP, FABP9) and FABP12, and three of which are expressed in the brain, including FABP3, FABP5 and FABP7.

FABPs have diverse and highly specified roles in regulating the metabolism and actions of the ligands they bind. They are important targets for drug development and therapy for many metabolic diseases.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-101903
    BMS-309403
    		Inhibitor 99.93%
    BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.
    BMS-309403
  • HY-101903A
    BMS-309403 sodium
    		Inhibitor 99.94%
    BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.
    BMS-309403 sodium
  • HY-145990
    FABPs ligand 6
    		Inhibitor 99.86%
    FABPs ligand 6 (MF6) is an FABP5 and FABP7 inhibitor with KD values of 874 nM and 20 nM, respectively. FABPs ligand 6 can be used for multiple sclerosis research.
    FABPs ligand 6
  • HY-148665
    FABP-IN-2
    		Inhibitor 99.78%
    FABP-IN-2 is a novel FABP3 ligand. FABP-IN-2 inhibits FABP3/FABP4 with an IC50 of 1.16 μM and 4.27 μM respectively.
    FABP-IN-2
  • HY-159115
    ART26.12
    		Inhibitor 99.57%
    ART26.12 is an orally active FABP5 inhibitor with anti-cannabinoid properties. ART26.12 effectively prevents and alleviates Oxaliplatin (HY-17371)-induced pain through lipid modulation and cannabinoid receptor activation.
    ART26.12
  • HY-117506B
    SBFI-26
    		Inhibitor 99.05%
    SBFI-26 is a selective and competitive inhibitor of fatty acid binding proteins FABP5 and FABP7, with Kis of 0.9 µM and 0.4 µM for FABP5 and FABP7, respectively. SBFI-26 produces anti-nociceptive and anti-inflammatory effects.
    SBFI-26
  • HY-161892
    FABP4-IN-4
    		Inhibitor
    FABP4-IN-4 (Compound 30) is an orally active inhibitor for FABP, with IC50 of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models.
    FABP4-IN-4
  • HY-158127
    FABP1-IN-1
    		Inhibitor 99.95%
    FABP1-IN-1 (44) is a selective FABP1 inhibitor, with an IC50 of 4.46 μM. FABP1-IN-1 (44) can be used for the research of NASH.
    FABP1-IN-1
  • HY-101503
    HTS01037
    		Antagonist 99.84%
    HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.
    HTS01037
  • HY-161702
    RO6806051
    		Inhibitor 99.84%
    RO6806051 (compound12) is a potent dual fatty acid binding protein 4 and 5 (FABP4 and FABP5) inhibitor with good selectivity and absorption, distribution, metabolism and excretion (eADME) properties.
    RO6806051
  • HY-P4115
    CooP
    CooP is a linear glioblastoma-targeting nonapeptide. CooP binds to the mammary-derived growth inhibitor/fatty acid binding protein 3 (FABP3) in the glioblastoma cells and its associated vasculature. CooP is used for the targeted delivery of chemotherapy and different nanoparticles.
    CooP
  • HY-149953
    FABP4-IN-2
    		Inhibitor
    FABP4-IN-2 (Compd 10g) is a selective and orally active FABP4 inhibitor with the Ki values of 0.51 μM for FABP4, 33.01 μM for FABP3. FABP4-IN-2 can be used in the research of inflammation-related diseases.
    FABP4-IN-2
  • HY-160456
    FABP4/5-IN-4
    		Inhibitor
    FABP4/5-IN-4 (compound E1) is a potent inhibitor of FABP4 and FABP5, with the IC50s of 3.78 μM and 5.72 μM, respectively. FABP4/5-IN-4 plays an important role in metabolism disorder like diabetes mellitus.
    FABP4/5-IN-4
  • HY-160457
    FABP4/5-IN-5
    		Inhibitor
    FABP4/5-IN-5 (compound D9) is a potent inhibitor of FABP4 and FABP5,? with the IC50s of 4.68 μM and 10.72 μM, respectively.FABP4/5-IN-5 plays an important role in metabolism disorder like diabetes mellitus.
    FABP4/5-IN-5
  • HY-117562
    a-FABP-IN-1
    		Inhibitor
    a-FABP-IN-1 (Compound 5g) is a potent and selective human adipocyte fatty acid-binding protein (a-FABP) inhibitor with a Ki below 1.0 nM. a-FABP-IN-1 inhibits the pro-inflammatory cytokine production.
    a-FABP-IN-1
  • HY-163032
    FABP4-IN-3
    		Inhibitor
    FABP4-IN-3 (compound C3) is a highly selective FABP4 inhibitor (FABP4 Ki = 25 ± 3a nM, FABP3 Ki = 15.03 μM) which exhibits a 601-fold selectivity over FABP3. FABP4-IN-3 also shows metabolic stability and potent cellular anti-inflammatory activity, making it promising to get involved in the research of metabolic disease, cardiac dysfunction and inflammation-related disease.
    FABP4-IN-3
Cat. No. Product Name / Synonyms Application Reactivity